| Description |
1 online resource |
| Contents |
Preface; Contents; 1: Treatment of€Chronic Hepatitis C with€the€First-Generation Protease Inhibitor Telaprevir: Its Efficacy and€Resistance Mutations; 1.1 Introduction; 1.2 Protease Inhibitors; 1.3 Telaprevir; 1.3.1 Clinical Trial Results; 1.3.2 Triple Therapy in€Clinical Practice; 1.3.3 Triple Therapy for€Genotype 2 Patients; 1.3.4 Telaprevir Treatment and€Resistance Mutations; 1.3.5 The Current Role of€Triple Therapy with€TVR; 1.4 Conclusion; References; 2: Features of€the€Second Wave of€the€First Generation Protease Inhibitors: Effect and€Tolerance; 2.1 Introduction |
|
2.2 Simeprevir2.3 Asunaprevir; 2.4 Vaniprevir; 2.5 Paritaprevir; 2.6 Conclusion; References; 3: The Efficacy of€Daclatasvir Plus Asunaprevir Combination Therapy with€Chronic Hepatitis; 3.1 Introduction; 3.2 DAA Mechanisms of€Action; 3.2.1 Protease Inhibitors: Asunaprevir; 3.2.2 NS5A Inhibitors: Daclatasvir; 3.3 Phase 3 Results of€Daclatasvir Plus€Asunaprevir Therapy in€Japan; 3.3.1 Treatment Results in€Patients Who Did Not Respond to€IFN-Based Therapy and€Patients Who Are IFN-ƯIneligible/Intolerant; 3.3.2 Treatment Results in€Treatment-Naïve Patients and€Prior Interferon Relapsers |
|
3.4 Appearance of€Resistance-Associated Variants in€Patients with€Virologic Failure3.5 Treatment Results After Approval of€the€Therapy; 3.6 Indications and€Cautions; 3.7 Conclusion; References; 4: Resistance-Associated Variants in€the€NS5A Region of€HCV and€Methods for€the€Detection; 4.1 Characteristics of€HCV-NS5A and€the€Action Sites of€NS5A Inhibitors; 4.2 Assay Systems to€Detect and€Quantify NS5A-RAVs of€Genotype-1b HCV; 4.3 Significance of€Amino Acid Mutations in€the€NS5A Region in€Patients with€HCV Infection; 4.4 Therapeutic Efficacies of€DAAs and€NS5A Polymorphisms; References |
|
5: Detection of€Antiviral Drug-Resistant Variants in€Chronic Hepatitis C by Deep Sequencing5.1 Introduction; 5.2 Deep Sequencing Analysis of€RAVs and€the€Aim of€RAV Analysis; 5.3 Interferon-Based DAA Therapy; 5.3.1 TVR/PEG-IFN/RBV Combination Therapy; 5.3.2 SMV/PEG-IFN/RBV Combination Therapy; 5.4 Interferon-Free DAA Therapy; 5.5 Conclusions; References; 6: Incidence and€Characteristics of€Naturally Occurring Drug-Resistant Hepatitis C Virus Strains; 6.1 Introduction; 6.2 Naturally Occurring Protease Inhibitor-Resistant Variants |
|
6.3 Naturally Occurring NS5A Inhibitor-Resistant Variants6.4 Naturally Occurring NS5B Inhibitor-Resistant Variants; 6.5 Conclusion; References; 7: Treatment Effects and Resistance-Associated Variants of Sofosbuvir Regimen for Japanese Patients with Chronic Hepatitis C Virus Genotypes 1 and 2; 7.1 The Mechanism of€Action of€Sofosbuvir and€a€Note of€Caution; 7.2 Characteristics of€Sofosbuvir; 7.3 Sofosbuvir/Ribavirin Therapy for€Genotype 2; 7.3.1 Study Design and€Patients Characteristics; 7.3.2 Efficacy and€Safety; 7.3.3 NS5B RAVs and€Sofosbuvir/Ribavirin Therapy |
| Summary |
This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students |
| Notes |
Online resource; title from PDF title page (SpringerLink, viewed November 11, 2016) |
| Subject |
Hepatitis C -- Treatment
|
|
Hepatitis C virus.
|
|
Outcome assessment (Medical care)
|
|
Hepacivirus -- drug effects
|
|
Hepatitis C -- drug therapy
|
|
Antiviral Agents -- therapeutic use
|
|
Drug Resistance, Viral
|
|
Treatment Outcome
|
|
Hepacivirus
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Outcome assessment (Medical care)
|
|
Hepatitis C -- Treatment
|
|
Hepatitis C virus
|
| Form |
Electronic book
|
| Author |
Chayama, Kazuaki, editor
|
| ISBN |
9789811024160 |
|
9811024162 |
|
